BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

KeyBanc lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps an Overweight rating on the shares. The firm notes healthcare ...

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $6.25, a high estimate of $7.00, and a low estimate of $6.00. Highlighting a 26.47% decrease ...

Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.15 or 3.39% from the prior close of $4.42. The stock opened at $4.41 and touched ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report.